A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)

Trial Profile

A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms ESTEEM
  • Sponsors Biogen
  • Most Recent Events

    • 28 Apr 2017 1-year safety and efficacy results (n=2025; as of 12 Apr 2017), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 06 Apr 2017 Planned End Date changed from 1 Feb 2022 to 28 Feb 2024.
    • 06 Apr 2017 Planned primary completion date changed from 1 Feb 2022 to 28 Feb 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top